Corporate Profile
First Tracks Biotherapeutics is a clinical‑stage biotechnology company pioneering innovative immunology therapeutics, focusing on developing antibodies that modulate key immune pathways involved in autoimmunity and inflammation. Its pipeline of potentially best-in-class antibodies, includes ANB033, a CD122 antagonist, in development for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter, in development for rheumatoid arthritis; and ANB101, a BDCA2 modulator.
Presentations
